{"name":"Arcellx, Inc.","slug":"arcellx","ticker":"ACLX","exchange":"NASDAQ","domain":"arcellx.com","description":"Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy pro","hq":"Redwood City, CA","founded":0,"employees":"209","ceo":"Rami Elghandour","sector":"Cell Therapy / Biotech","stockPrice":115.07,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.7B","metrics":{"revenue":22286000,"revenueGrowth":-89.2,"grossMargin":0,"rdSpend":0,"netIncome":-228934000,"cash":450334016,"dividendYield":0,"peRatio":-77.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ARC-T Cells","genericName":"ARC-T Cells","slug":"arc-t-cells","indication":"Other","status":"phase_1"},{"name":"SPRX002","genericName":"SPRX002","slug":"sprx002","indication":"Other","status":"phase_1"},{"name":"anito-cel","genericName":"anito-cel","slug":"anito-cel","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARC-T Cells","genericName":"ARC-T Cells","slug":"arc-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SPRX002","genericName":"SPRX002","slug":"sprx002","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"anito-cel","genericName":"anito-cel","slug":"anito-cel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Arcellx Announces FDA Clearance of Investigational New Drug (IND) Application for AC207","summary":"Arcellx announced that the FDA has cleared the IND application for AC207, enabling the company to initiate a Phase 1 clinical trial.","drugName":"AC207","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Arcellx Reports Third Quarter 2023 Financial Results","summary":"Arcellx reported its third-quarter 2023 financial results, highlighting a significant increase in revenue and a strong pipeline of clinical candidates.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"deal","headline":"Arcellx Enters into Strategic Collaboration with Merck KGaA","summary":"Arcellx announced a strategic collaboration with Merck KGaA to develop and commercialize AC207, a CD19-targeting CAR-T cell therapy.","drugName":"AC207","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVmdubTJOVGgxSnNweVRYM041cmM5NWNUdWhFdU85VTVtcV82amV6WTNLSGtMT2pVZHQzb1R5RlVzNUEzMk5GcHdCZ1FVN1hndXNwRVlya0VMREhhZUR3YUhpUklEbk51WnVmaFEwbDh4YUd0ZkpvRmNUYWRMcUNSQ0N5YjBuaFJwQ1FDbU4zZw?oc=5","date":"2026-03-10","type":"deal","source":"Finviz","summary":"Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Finviz","headline":"Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOQ0ZySzdRY3lJemNud0p1a3dfQUhJZnZxWVJ6Z3RPQkJBaUpseEtyOGN2dGZRbzgwdG9lNWw4MGlJOWxXa3RIM3BmUWN4OGFTOG03VjFQUXVDNHp3MDdOUW8tcE1HWWg2ZG1HajRSbWJ6RzBORUpSOVRtNVJ6XzNuLWVxc2ZQakpGNmtQSXMyMXQxeDB0UEVrZGxFcjJzN1lLakFqdjU3OXp4ZTBTQVVINER3VkVUdU1jMEk4TEluN25JU1NXdUJVTk9NMUVEbEo1U1VQbExxRk4zdw?oc=5","date":"2026-02-24","type":"deal","source":"Eastern Progress","summary":"GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - Eastern Progress","headline":"GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxOX3NLcEFqNmpEZ1FiV2dlMDlCRWVKeTJ6OEYwRnJxOUlsVlBhWDN5cXI4Z2JDdzNaWTRPb0ZxZUhobEJtU0NxazZLNHRkblJaeThxM3ZYdFNKbmxxS2VLMTQ4QUVTVEhQcGE5ZkQwSlNQNm94YUxOdU41eldjNlB4bVNfNFF3WENHNTVrVUVKckFCQk1YdE1qYU82am4xaHg0Q3R5ZTExRkVfVjZtSl9lbGtKNjRMLUExbi1XSzhzWFlxLXByYVI0aWhTWEUzcUZ2SHZwTVIwZHdEb2JZQzZiQlVERFlqYnplRk56N3NaZTNYVVdWN3IzUTE0aFFBSEk4RFFiamw3a3FQUmN2RTgwN0hMWjZKa3JJckNnem44UGZzOVdIMEFZc1VabmJSMWlIaTdDMlNVTXU4a19Kd0V0UFNRSGZkZw?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) - The Globe and Mail","headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX) and Fisher & Paykel Healthcare Co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNeHFKZnB0ZURwWWhDam9ndFJiMmVLRkJFeGRyQnBycUFjOXFSc0toS1FSbWN2eXc4YkxwamJ1eUFNTkh1VGRNOC1LUWRZenhCT1NfMkZNMXJyZWlfbmxROURpSUNnTFdlSWs2MVZGeG5tRjFuQUNxSC1ORTducE9UMV9CQlRlRWU2UnozX2NGZC3SAZYBQVVfeXFMTnZqWDdTa0pQR0JXSnVLdzdiU2ZPRWRjOTRGRVJOOS1UVk0yRTl6Q1Z4Q1Q5VVRwUDhDWnVfQTNPak5JUk4zb3lQMHp5WXMxemVNNUljRDhKUzlucEl1RFd0dzdTeUEtUEdCWmdQZzZnQ01rbUJ0SEVpaGNWU0x2ZDRlS2lpZnNsdTh4Q1NRSm12MDhtNnF3?oc=5","date":"2026-02-23","type":"deal","source":"cnbc.com","summary":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion - cnbc.com","headline":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNU0dTYnliaW9YYUgzMHdNRHZHRTdSQkJBMkJrUjh0eFZRbjNscmhCWllDT3ZELW50UE5kOFoyVGNiR0I4S3h5Z3lNYU93ZU5WaURlbVFQUzNUSmt4V3F1c3VNbW11YmxELXZYQW9wcVZib19HZWMwWkNabEFOcHQtcDV2RlIxeVlFb0ZaVmZVMkhmalE?oc=5","date":"2026-02-23","type":"deal","source":"Reuters","summary":"Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters","headline":"Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMXJab09HTkI3Z251V0pEOC1TX0piWkNkNXhXXzVTZkVVV0NTN0lFZ2gtZHVDOEFocHJqREFSZE1IcWxIWVRyVEItRGNGUTh2WnRwYzVEcnJqZ3VtazdSUjdQV2gyb25nUFg0RmlYRWI3UXp4OGptcnI0aERuUURuUDFEaXFnazdHenR4QTZjYmxsSl9wTWc?oc=5","date":"2026-02-23","type":"pipeline","source":"bioworld.com","summary":"Gilead brings Arcellx fully under the fold for $7.8B - bioworld.com","headline":"Gilead brings Arcellx fully under the fold for $7.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8yVVQwT1hHTU5ITk1XLW1kdm1uTXdYclpFUERxMC1KZHBhQU1Ld0tWZ1U0VDlJR1NaUnM0azFQTXVSSTRGblVJQzVUa2JCSy1ubFRVcDZoa3RTa0NWYVRkVEx5TWU2Y1dOOHF4VnRFR2hGS2ZNbnY4Z3JxNmlMeDA?oc=5","date":"2026-02-23","type":"deal","source":"Tokenist","summary":"Why Did Arcellx (ACLX) Stock Surge 70%? $7.8B Buyout Deal - Tokenist","headline":"Why Did Arcellx (ACLX) Stock Surge 70%? $7.8B Buyout Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQY25CRllUR3pseUdIV3I0ZEtPajVTd1RwNFBsLTlKZlROdUJ6RkNwMmlYWDBST3d1b0dOaWpVTXU0S1A2bXYxWFZicXVWSTA4V0RITHNPdkFvY0ZYZFJWSU05VDhVaUxkcDFmSmdzeWJIak43UjVKRk96dVBxRW92SkVhUzFBOXNJa3I2TWdtaUxwZ3VpMzR1Rmh2YUdUcTFjWGxsT0QtYWMwa3NNTEtMNWtCYlhjLUlTT2lGVndxYXl6UXFyZzI3R2NDM3JYU1BSemo0Mm11REIydHd3TW51OFZZX3QtTUlOS1RkNkZwOWRRU1ZtWkY3SGdRc1drUQ?oc=5","date":"2026-02-23","type":"earnings","source":"Sahm","summary":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Sahm","headline":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"pipeline","source":"simplywall.st","summary":"Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results - simplywall.st","headline":"Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPRmJEY0xtcTFLTFZTbzNNQXJxVEFyV1VOVFM5ODRMbkJEQm81MUJPVl94Wm1JSFlDRExwNG1RaWJDMFQxYUw5YlVzVHRjMVRtek5tZ3pYRkNtNzNqT2RSR09qbXBOcmY3Ty1WamhSWFlHVzlPVlhscXBZay12X2JVc1Zfa1ZnZkhOWVZ5dklPdmdEaHBsbVdnUU5lTHRCUDIweWdUSjlwcUFOTzhVd0pXWFhObEJMa0lFTmc?oc=5","date":"2025-07-15","type":"pipeline","source":"Seeking Alpha","summary":"Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha","headline":"Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOcURnUENCek1OSk5kN3dVVG51UmVVb29VbnNJVFY2Y2NqYW9rZ2ltOVhKdkhEb1pSZXdtOEZhN21DZDNveXUwekFIOHFKQ2NTN25POGdSc3c1NWVaVXRXQXA1dG14Z0Y2UGs1M3pyVjB0NkpYdkdDZldDQ1BTcko2Y0hxbmJEdy1MQnJaNWh4MUV0UzQxMzRRdEd1T09oOGFCWjdFVV9GWUF1NXFCTlBXMnBVVVpQREpSWVJvMkxzUGcwSmVEckstUTIzc3NlOWs?oc=5","date":"2025-05-08","type":"earnings","source":"Business Wire","summary":"Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire","headline":"Arcellx Provides First Quarter 2025 Financial Results and Business Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9QdU9XaWJUWE9UNUt5UkNBdHBJaW05ODAyS1hTWkxQd1FHS2JJdEZBbzVUNDRpQ3ZGYUxTNEczbWY0aThpdEZoQmI3WXN2ME1GVHJv?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ACLX Stock Price, News & Analysis - Stock Titan","headline":"ACLX Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Oncology"],"financials":{"source":"yahoo_finance","revenue":22286000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":22286000},{"period":"2024-12-31","value":107936000},{"period":"2023-12-31","value":110319000},{"period":"2022-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":157611000,"rdSpendHistory":[{"period":"2025-12-31","value":157611000},{"period":"2024-12-31","value":157093000},{"period":"2023-12-31","value":133849000},{"period":"2022-12-31","value":149555000}],"sgaSpend":117758000,"operatingIncome":-253083000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-253083000},{"period":"2024-12-31","value":-137571000},{"period":"2023-12-31","value":-89880000},{"period":"2022-12-31","value":-191259000}],"netIncome":-228934000,"netIncomeHistory":[{"period":"2025-12-31","value":-228934000},{"period":"2024-12-31","value":-107348000},{"period":"2023-12-31","value":-70690000},{"period":"2022-12-31","value":-188679000}],"eps":-2,"epsHistory":[{"period":"2024-12-31","value":-2},{"period":"2023-12-31","value":-1.47},{"period":"2022-12-31","value":-5.19},{"period":"2021-12-31","value":-1.936856}],"cash":80262000,"cashHistory":[{"period":"2025-12-31","value":80262000},{"period":"2024-12-31","value":105679000},{"period":"2023-12-31","value":394583000},{"period":"2022-12-31","value":64179000}],"totalAssets":603990000,"totalLiabilities":201639000,"totalDebt":51919000,"equity":402351000,"operatingCashflow":-210258000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-210258000},{"period":"2024-12-31","value":-83467000},{"period":"2023-12-31","value":207573000},{"period":"2022-12-31","value":-99303000}],"capex":-2327000,"capexHistory":[{"period":"2025-12-31","value":-2327000},{"period":"2024-12-31","value":-13434000},{"period":"2023-12-31","value":-21428000},{"period":"2022-12-31","value":-2277000}],"freeCashflow":-212585000,"dividendsPaid":null,"buybacks":0,"employees":209,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":31242000,"ebit":-58084000,"ebitda":-56443000,"period":"2025-12-31","revenue":1654000,"epsBasic":null,"netIncome":-58112000,"rdExpense":34095000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-63683000},{"sga":31637000,"ebit":-55781000,"ebitda":-53938000,"period":"2025-09-30","revenue":4949000,"epsBasic":-0.99,"netIncome":-55781000,"rdExpense":35088000,"epsDiluted":-0.99,"grossProfit":null,"operatingIncome":-61776000},{"sga":28653000,"ebit":-52742000,"ebitda":-51124000,"period":"2025-06-30","revenue":7554000,"epsBasic":-0.94,"netIncome":-52771000,"rdExpense":37627000,"epsDiluted":-0.94,"grossProfit":null,"operatingIncome":-58726000},{"sga":26226000,"ebit":-62258000,"ebitda":-60682000,"period":"2025-03-31","revenue":8129000,"epsBasic":-1.13,"netIncome":-62270000,"rdExpense":50801000,"epsDiluted":-1.13,"grossProfit":null,"operatingIncome":-68898000},{"sga":23769000,"ebit":-45569000,"ebitda":-43780000,"period":"2024-12-31","revenue":15266000,"epsBasic":null,"netIncome":-47081000,"rdExpense":44649000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-53152000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.48,"netIncome":null,"rdExpense":null,"epsDiluted":-0.48,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":115.07,"previousClose":0,"fiftyTwoWeekHigh":115.13,"fiftyTwoWeekLow":50.85,"fiftyTwoWeekRange":"","fiftyDayAverage":112.62,"twoHundredDayAverage":84.15,"beta":0.25,"enterpriseValue":6330856960,"forwardPE":-77.7,"priceToBook":16.57,"priceToSales":302.09,"enterpriseToRevenue":284.07,"enterpriseToEbitda":-25.69,"pegRatio":0,"ebitda":-246404992,"ebitdaMargin":0,"freeCashflow":-97093872,"operatingCashflow":-210258000,"totalDebt":51919000,"debtToEquity":12.9,"currentRatio":4.43,"returnOnAssets":-24.1,"returnOnEquity":-53.4,"analystRating":"","recommendationKey":"hold","numberOfAnalysts":10,"targetMeanPrice":112.2,"targetHighPrice":120,"targetLowPrice":82,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.7,"institutionHeldPercent":90.3,"sharesOutstanding":58506348,"floatShares":42958685,"sharesShort":1800274,"shortRatio":1.56,"shortPercentOfFloat":3.1,"epsTrailing":-4.07,"epsForward":0,"revenuePerShare":0.4,"bookValue":6.95,"officers":[{"age":46,"name":"Mr. Rami  Elghandour","title":"Chairman of the Board, CEO & President"},{"age":32,"name":"Ms. Michelle Lim Gilson","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Aileen  Fernandes","title":"Chief Operating Officer"},{"age":53,"name":"Mr. Narinderjeet  Singh M.S.","title":"Chief Technical Officer"},{"age":null,"name":"Dr. Heba  Nowyhed Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Myesha  Lacy","title":"Chief Investor & Communications Officer"},{"age":null,"name":"Ms. Maryam  Abdul-Kareem J.D., M.S.","title":"General Counsel & Chief Legal Officer"},{"age":null,"name":"Ms. Kate  Aiken","title":"Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.arcellx.com","phone":"240 327 0630"}}